Sachetta LLC Has $29,000 Stock Position in Xenetic Biosciences Inc (NASDAQ:XBIO)

Posted by Samantha Reynolds on Jan 26th, 2025

Sachetta LLC lessened its position in shares of Xenetic Biosciences Inc (NASDAQ:XBIO – Free Report) by 57.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,371 shares of the company’s stock after selling 10,000 shares during the quarter. Sachetta LLC owned approximately 0.48% of Xenetic Biosciences worth $29,000 as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Check Out Our Latest Research Report on XBIO

Xenetic Biosciences Price Performance

Xenetic Biosciences stock opened at $4.24 on Friday. The business has a 50 day simple moving average of $4.16 and a 200 day simple moving average of $4.00. The company has a market capitalization of $6.54 million, a PE ratio of -1.59 and a beta of 2.22. Xenetic Biosciences Inc has a one year low of $2.78 and a one year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million. Equities analysts anticipate that Xenetic Biosciences Inc will post -1.01 earnings per share for the current fiscal year.

Xenetic Biosciences Profile

(Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.